

Sisram Medical Adds Chinese Stock Trading Name to Better Connect with Asia-Pacific Market and Explore Business Expansion

HONG KONG, December 10th, 2018 -- Sisram Medical Ltd ("Sisram" or "the Company") (Hong Kong: 1696), an investment holding company specializing in medical technology for healthcare, today announced it will add a Chinese stock trading name in order to better connect with the Asia-Pacific market and explore business expansion.

Effective on December 13th, 2018, the Company's shares will trade on the Stock Exchange of Hong Kong with bilingual names. The added Chinese name is “复锐医疗科技”, pronounced “Fu Rui Yi Liao Ke Ji” in Mandarin. The English stock short name of the Company will remain as “Sisram Med”.

In the new Chinese trading name, the first character 复 “fu”, the same as the first character used for Fosun “复星”, is an indication of Sisram's solid backing as a member of the Fosun family of companies. “锐” represents surging ahead to lead technology innovation. “医疗科技” is Sisram's business positioning. With its roots in China, and through technology and innovation, Fosun's mission is to create customer-to-maker (C2M) ecosystems in health, happiness and wealth, providing high-quality products and services for families around the world. As Sisram's controlling shareholder, Fosun Pharma will leverage its global operations and advantages in the health industry to support Sisram to diversify its technologies and businesses, while strengthening its market leadership in China and around the world.

“We are pleased to announce this change. Adding the Chinese trading name “复锐医疗科技” will better connect us with the Asia-Pacific market, and communicate our vision in the medical technology industry,” said Mr. Lior Dayan, CEO of Sisram, “The greater Asian market for Medical Technology, especially the China market, is fast growing. Sisram, as an industry leader, aims to continue its expansion in this market to become the leading global facilitator for enhancing quality of life.”

“With the added Chinese trading name, investors can better understand our positioning, and the bilingual names also clearly articulate our future growth strategy,” said Mr. Yi Liu, Chairman and Executive Director of Sisram. “Sisram, a pioneer in MedTech at Fosun Pharma, will continue to meet the market demand for surgical and medical aesthetic solutions, and grow into a technology-driven comprehensive platform for medical equipment by business expansion and resources integration.”

No action is needed from current shareholders in relation to the addition of the Chinese stock trading name.

About Sisram Medical Ltd

Sisram Medical Ltd (1696.HK), the first Israeli company listed on the Hong Kong Exchange Main Board, was established in 2013 for the acquisition of Alma, a leading provider of energy-based surgical and medical aesthetic solutions, ranked No. 1 in the People's Republic of China and one of the top 5 global leaders in its industry. Sisram Medical is majority held by Fosun Pharma, a leading health & medical industry group in China.

Sisram Medical – Enhancing Quality of Life.

<http://www.sisram-medical.com>

For media inquiries, please contact:

ICR Inc.

Edmond Lococo

Tel: +86 (10) 6583-7510

E-mail: Edmond.lococo@icrinc.com